Entradas

Latest Developments in the Management of Nut Allergies

 Latest Developments in the Management of Nut Allergies Authors:  H A Brough, R Gourgey, S Radulovic, J C Caubet, G Lack, A Anagnostou Abstract: Purpose of review: In this review, we sought to describe the most recent advances in the dietary and medical management of peanut and tree nut allergy, including selective introduction and immunotherapy. Recent findings: Dietary updates include changes to labeling laws, improved information sources, and new apps for buying foods in shops and overseas to better protect individuals with nut allergies. There are still issues in the management of nut allergies in schools, such as parents having to resort to packed lunches instead of school meals and patients experiencing bullying. Air travel also poses concern, but additional resources are now available to travelers, and recent evidence suggest limited airborne exposure to nuts. The medical management of anaphylaxis is use of epinephrine; however, this remains underutilized. Needle length...

Effects of pregnancy on chronic urticaria: Results of the PREG- CU UCARE study

 Effects of pregnancy on chronic urticaria: Results of the PREG-CU UCARE study Authors: Emek Kocatürk, Mona Al-Ahmad, Karoline Krause, Ana M Gimenez-Arnau, Simon Francis Thomsen, Niall Conlon, Alexander Marsland, Ekin Savk, Roberta F Criado, Inna Danilycheva, Daria Fomina, Kiran Godse, Maryam Khoshkhui, Aslı Gelincik, Ece Nur Degirmentepe, Semra Demir, Luis Felipe Ensina, Alicja Kasperska-Zajac, Michael Rudenko, Solange Valle, Iris Medina, Andrea Bauer, Zuotao Zhao, Petra Staubach, Laurence Bouillet, Özlem Su Küçük, Can Ateş, Marcus Maurer Abstract: Background: Chronic urticaria (CU) predominantly affects women, and sex hormones can modulate disease activity in female CU patients. As of now, the impact of pregnancy on CU is largely unknown. Aim: To analyze the course and features of CU during and after pregnancy. Patients and methods: PREG-CU is an international, multicenter study of the Urticaria Centers of Reference and Excellence (UCARE) network. Data were collected via a 47-ite...

Reactivation of Varicella Zoster Virus after Vaccination for SARS-CoV-2

Reactivation of Varicella Zoster Virus after Vaccination for SARS-CoV-2 Authors:  Mina Psichogiou, Michael Samarkos, Nikolaos Mikos, and Angelos Hatzakis Abstract: Seven immunocompetent patients aged > 50 years old presented with herpes zoster (HZ) infection in a median of 9 days (range 7–20) after vaccination against SARS-CoV-2. The occurrence of HZ within the time window 1–21 days after vaccination defined for increased risk and the reported T cell-mediated immunity involvement suggest that COVID-19 vaccination is a probable cause of HZ. These cases support the importance of continuing assessment of vaccine safety during the ongoing massive vaccination for the COVID-19 pandemic and encourage reporting and communication of any vaccination-associated adverse event. DOI:   10.3390/vaccines9060572

Transitioning From Immunosuppressants to Dupilumab in Pediatric Atopic Dermatitis

Transitioning From Immunosuppressants to Dupilumab in Pediatric Atopic Dermatitis Authors: Catherine M. Ludwig,  Jennifer L. Hsiao, Peter A. Lio, and Vivian Y. Shi Abstract: Dupilumab has recently been approved by the Food and Drug Administration for use for treatment of moderate to severe atopic dermatitis in children aged 6 to 11 years. It presents a novel treatment option with a favorable safety profile for patients who are currently reliant on immunosuppressants, including cyclosporine A, methotrexate, and mycophenolate mofetil. Particularly during the current COVID-19 pandemic, immunosuppression should be avoided to retain intrinsic antiviral immunity. Transitioning to dupilumab should be executed strategically tapering immunosuppressants and minimizing risk of flare by overlapping with the biologic. Herein, we use results of outcome measurements from LIBERTY AD ADOL and LIBERTY AD PEDS trials of dupilumab in adolescents aged 12 to 18 years and children aged 6 to 11 years, res...

Wet Wrap Therapy in Moderate to Severe Atopic Dermatitis

Wet Wrap Therapy in Moderate to Severe Atopic Dermatitis Authors:   Noreen Heer Nicol, Mark Boguniewicz Key points: - Atopic dermatitis (AD) remains a complex, common, chronic, and relapsing skin disorder, and a global public health problem. - National and international guidelines address AD care in a stepwise fashion. Wet wrap therapy (WWT) is a therapeutic intervention for moderate to severe AD. - WWT plays an important role as an acute therapeutic intervention for management of moderate to severe AD used with undiluted topical corticosteroids of appropriate potency. - WWT should not be used for mild AD or as a chronic or maintenance therapy. - WWT should be considered as a treatment option ahead of the systemic therapies for pa- tients failing conventional topical therapy. DOI:   10.1016/j.iac.2016.08.003

Benefits of baked milk oral immunotherapy in French children with cow's milk allergy

Benefits of baked milk oral immunotherapy in French children with cow's milk allergy Authors:   Vianney Gruzelle, Agnès Juchet, Audrey Martin-Blonde, Marine Michelet, Anne Chabbert-Broue, Alain Didier Abstract:  Background: Introduction and gradual incremental escalation of a low dose of baked milk may accelerate the resolution of severe cow's milk (CM) allergy for some children. The purpose of our study was to evaluate the efficacy and safety of baked milk oral immunotherapy (OIT) in children with CM allergy after a low-dose baked milk oral food challenge (OFC). Methods: In a retrospective analysis of OFC performed between 2013 and 2018 at the Children's Hospital of Toulouse (France), we identified 64 children with CM allergy and high milk and casein-specific IgE levels, who underwent a total of 171 milk OFC. Mean age at 1st OFC was 4.8 years. Mean CM-specific IgE was 47.9 kUA/L, and mean casein-specific IgE was 42.3 kUA/L. Results: Most children were...

Contact urticaria: Frequency, elicitors and cofactors in three cohorts (Information Network of Departments of Dermatology; Network of Anaphylaxis; and Department of Dermatology, University Hospital Erlangen, Germany)

Contact urticaria: Frequency, elicitors and cofactors in three cohorts (Information Network of Departments of Dermatology; Network of Anaphylaxis; and Department of Dermatology, University Hospital Erlangen, Germany) Authors: Helene Süß, Sabine Dölle-Bierke,  Johannes Geier, Burkhard Kreft, Eva Oppel, Claudia Pföhler, Christoph Skudlik, Margitta Worm, Vera Mahler Abstract:   Background: Contact urticaria (CU) is an infrequent, mostly occupational disease that may be life-threatening (CU syndrome stage 4). Objectives: To identify the current frequency, elicitors and cofactors of CU. Patients: Three cohorts were retrospectively analysed for CU: (a) patients from the Information Network of Departments of Dermatology (IVDK) database (2000-2014; n = 159 947); (b) patients from an allergy unit (Department of Dermatology, University Hospital Erlangen, 2000-2015; n = 4741); and (c) patients from the Anaphylaxis Registry (2007-2015: 6365 reported cases, in...